United States: WilmerHale Advises Visterra In $46.7M Series C Financing
Last Updated: October 24 2017

On October 5, 2017, Visterra, Inc., a clinical-stage biotechnology company that uses its novel Hierotope® platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against such targets that are not adequately addressed with conventional approaches, announced that it has completed a Series C financing round raising a total of $46.7 million, including a new extension totaling $23.6 million.

The WilmerHale team representing Visterra in this transaction included Lia Der Marderosian, Molly Fox, Emily Gainor and Sam Rothberg.

Visterra's press release is available at www.visterrainc.com.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Frédéric Louis, Christian Duvernoy, Dr. Martin Braun, D. Reed Freeman, Jr., Itsiq Benizri
By Frédéric Louis, Christian Duvernoy, Dr. Martin Braun, D. Reed Freeman, Jr., Itsiq Benizri
By Naboth van den Broek, David S. Cohen, Ronald Meltzer, David Horn, Frédéric Louis, Georgia Tzifa
By Steven Finizio
By Chris Postizzi WilmerHale
By Lloyd Firth
By Mark Ford, Peter Spaeth, Holly Ovington
By Chris Postizzi WilmerHale
By Gregory Lantier, Brittany Amadi
By Anna Gaudoin
Tools
Print
Font Size:
Translation
Channels